Novartis agreed to acquire Synnovation Therapeutics’ PI3Kα inhibitor portfolio via a deal that pays $2 billion upfront, plus up to $1 billion in milestones, the companies announced. The purchase hands Novartis SNV4818 (Pikavation Therapeutics), a mutation‑selective oral PI3Kα candidate in early clinical testing intended to improve tolerability versus older PI3K inhibitors. The asset is being tested in HR+/HER2‑ breast cancer and other solid tumors with primary completion dates into 2027. Novartis framed the deal as defensive and strategic: it aims to shore up Piqray-era franchise positions with a more selective, potentially better‑tolerated inhibitor that could be combined in earlier lines of care.